Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib Combined With Selinexor for CAEBVD
NCT07369739Phase 3Recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of golidocitinib and selinexor in Epstein-Barr virus infection (EBV), sponsored by Beijing Friendship Hospital. Primary endpoints: Disease Activity at 8 weeks and Epstein-Barr Virus DNA at 8 weeks. Started Jan 2026; status: recruiting.
02
Drugs
golidocitinibselinexor
03
Conditions
Epstein-Barr virus infection (EBV)
Beyond the preview
Go deeper on NCT07369739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369739.